Valtech’s Cardioband for Mitral Valve Repair Receives Reimbursement in Germany
February 9, 2016—Valtech Cardio, Ltd. announced that it has received German Neue Untersuchungs und Behandlungsmethoden Status 1 approval for the Cardioband mitral reconstruction system, its flagship device for addressing mitral regurgitation (MR) in heart failure patients. Neue Untersuchungs und Behandlungsmethoden approval for the procedure grants reimbursement for Cardioband therapy in 70 leading hospitals in Germany, noted the company.
According to Valtech, which is headquartered in Or Yehuda, Israel, the Cardioband system combines a reconstruction implant, similar to those used in traditional surgical annuloplasty devices, with a transfemoral, transseptal delivery system. Sutureless connection of the implant to the mitral annulus is achieved using specially designed anchors. Reshaping of the mitral annulus to eliminate mitral regurgitation is done under physiological conditions and echocardiographic guidance for optimal results. Cardioband received CE Mark approval after clinical trial results demonstrated the device is a safe and efficacious intervention option for patients with functional mitral regurgitation.